SG11202101586QA - Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer - Google Patents

Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer

Info

Publication number
SG11202101586QA
SG11202101586QA SG11202101586QA SG11202101586QA SG11202101586QA SG 11202101586Q A SG11202101586Q A SG 11202101586QA SG 11202101586Q A SG11202101586Q A SG 11202101586QA SG 11202101586Q A SG11202101586Q A SG 11202101586QA SG 11202101586Q A SG11202101586Q A SG 11202101586QA
Authority
SG
Singapore
Prior art keywords
responsiveness
antibodies
marker
renal cell
cell cancer
Prior art date
Application number
SG11202101586QA
Other languages
English (en)
Inventor
Laurence Zitvogel
Valerio Iebba
Original Assignee
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave filed Critical Roussy Inst Gustave
Publication of SG11202101586QA publication Critical patent/SG11202101586QA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G06F17/18—Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Pure & Applied Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Computational Mathematics (AREA)
  • Mathematical Physics (AREA)
  • Mathematical Analysis (AREA)
  • Mathematical Optimization (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
SG11202101586QA 2018-09-28 2019-09-27 Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer SG11202101586QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306282.7A EP3629023A1 (fr) 2018-09-28 2018-09-28 Composition du microbiote comme marqueur de la réceptivité aux anticorps anti-pd1/pd-l1/pd-l2 dans le cancer de cellules rénales
PCT/EP2019/076158 WO2020064997A1 (fr) 2018-09-28 2019-09-27 Composition de microbiote, en tant que marqueur de réactivité à des anticorps anti-pd1/pd-l1/pd-l2 dans le cancer à cellules rénales

Publications (1)

Publication Number Publication Date
SG11202101586QA true SG11202101586QA (en) 2021-04-29

Family

ID=63798922

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101586QA SG11202101586QA (en) 2018-09-28 2019-09-27 Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer

Country Status (10)

Country Link
US (1) US20220056532A1 (fr)
EP (2) EP3629023A1 (fr)
JP (1) JP2022502038A (fr)
KR (1) KR20210068484A (fr)
CN (1) CN113287016A (fr)
AU (1) AU2019348525A1 (fr)
CA (1) CA3110671A1 (fr)
IL (1) IL280953A (fr)
SG (1) SG11202101586QA (fr)
WO (1) WO2020064997A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202007452D0 (en) * 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
KR102475860B1 (ko) * 2021-01-20 2022-12-07 전남대학교산학협력단 니볼루맙 치료 예후 예측을 위한 정보제공방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2876167A1 (fr) * 2013-11-21 2015-05-27 Institut Gustave Roussy Composition de la flore microbienne, comme marqueur de la réceptivité à la chimiothérapie et utilisation de modulateurs microbiens (pré-, pro- ou synbiotiques) pour améliorer l'efficacité d'un traitement du cancer
EP3209692B1 (fr) 2014-10-23 2024-05-22 Institut Gustave Roussy Procédés et produits permettant de moduler la composition du microbiote afin d'améliorer l'efficacité d'un traitement anticancéreux impliquant un inhibiteur des points de contrôle du système immunitaire
CA3047029A1 (fr) * 2016-12-22 2018-06-28 Institut Gustave Roussy Composition de microbiote, a titre de marqueur de reactivite a des anticorps anti-pd1/pd-l1/pd-l2 et utilisation de modulateurs microbiens pour ameliorer l'efficacite d'un traitement a base d'anticorps anti-pd1/pd-l1/pd-l2

Also Published As

Publication number Publication date
KR20210068484A (ko) 2021-06-09
EP3857229A1 (fr) 2021-08-04
EP3629023A1 (fr) 2020-04-01
AU2019348525A1 (en) 2021-05-13
CA3110671A1 (fr) 2020-04-02
JP2022502038A (ja) 2022-01-11
CN113287016A (zh) 2021-08-20
WO2020064997A1 (fr) 2020-04-02
IL280953A (en) 2021-04-29
WO2020064997A8 (fr) 2020-10-01
US20220056532A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
HK1210481A1 (en) Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use pd-l1 pd-l2
IL253569A0 (en) Antibodies against 3cd, antibodies against 23cd, and B-specific antibodies that specifically bind to 3cd or 23cd
SG11202102859TA (en) Antibodies binding to cd3
WO2016106159A8 (fr) Anticorps anti-pd-1
MX2018003689A (es) Proteinas de union a pd-1 y metodos para usarlas.
HK1210785A1 (en) Antibodies that bind to human programmed death ligand 1 (pd-l1) 1(pd-l1)
WO2015127136A3 (fr) Anticorps monoclonaux anti-ebola
HK1204557A1 (en) Antigen binding proteins that bind pd-l1 pd-1
HK1200736A1 (en) Anti-pd-l1 antibodies and uses thereof pd-l1
EP3298034A4 (fr) Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii
PH12014502406A1 (en) Anti-il-23p19 antibodies
IL280953A (en) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer
WO2013063613A3 (fr) Procédés et compositions associés à la neutralisation intracellulaire par une igg
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
EP3613770A4 (fr) Anticorps monoclonal à pd-l1
EP3247718A4 (fr) Modulation de variants de charge dans une composition d'anticorps monoclonaux
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
EP3468588A4 (fr) Expression de protéines de ligand d'activation de nkg2d pour sensibiliser les cellules cancéreuses à une attaque par des cellules immunitaires cytotoxiques
TW201613980A (en) Anti-tissue factor monoclonal antibody
EP3697895A4 (fr) Systèmes et méthodes pour produire des lymphocytes b génétiquement modifiés pour exprimer des anticorps sélectionnés
EP2785736A4 (fr) Dosages, anticorps, immunogènes et compositions se rapportant à 5-fu
EP3917952A4 (fr) Anticorps spécifiques à cd44
EP3931223A4 (fr) Anticorps se liant à pd-1
MX2014004969A (es) Anticuerpo monoclonal cd44 para el tratamiento de leucemia linfocita cronica de celulas b y otros padecimientos malignos hematologicos.